Novartis Leads MNC Generics Foray In China
This article was originally published in PharmAsia News
Most major pharmaceutical corporations allocate little or no resources to generic drug development. Novartis is bucking the trend with its pioneering efforts in this area. The company sees great opportunities in generics: mounting difficulties in approval of new drugs are leading to a global decline in patented drug development and production, while governments worldwide are increasing the proportion of generic drugs in their medical insurance coverage. In China, 70 percent of the pharmaceutical market is dominated by generic drugs, most of which are produced by local enterprises. Novartis China acknowledges the challenges of higher production costs and will focus on the strategy of brandname, quality and services to gain recognition. (Click here for more - Chinese Language)
You may also be interested in...
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.
Sun Pharma and its US Taro subsidiary have further criticized a recent CMS policy proposal that would see Medicare Part B drugs approved under the US hybrid 505(b)(2) pathway reimbursed at a lower rate applicable to multiple source products.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.